GLP 1 companion programs pitch employers on adherence as coverage shrinks
Noom, Omada, Virta and Twin Health told a Dallas conference that employers should pay for support around GLP 1 drugs. Virta cited over 80% one year adherence, but no data, prices or client names were published.
Who feels it
-
Payers
Rethink
Vendors pitch adherence and ROI to employers, but the 80% one year figure and the cost claims were not backed by published data on stage.
-
Patients
Adjust
Employer drug cover may come bundled with coaching or tracking programs; ask whether joining is required and what happens if the vendor leaves.
-
Sellers
Adjust
Omada's president called access only GLP 1 firms vending machines and predicted some companies will be gone within 36 months.
-
Prescribers
Worth knowing
Patients may arrive through vendor programs whose prescribers, records and refill routes can change if the company is sold or closes.
-
Pharmacies
Passes by
—
Four digital health companies told a Dallas audience on October 29 that employers should pay for GLP 1 companion programs, not the drug alone. Executives from Noom, Omada Health, Virta Health and Twin Health made the case at the MedCity INVEST Digital Health conference as more employers question the cost of weight loss cover. The pitch matters for access because coaching, nutrition help and tracking may become part of how some workers reach the medicine. The companies shared no prices, client names or published data on stage, according to the MedCity News account.
What four digital health firms told employers in Dallas
The panel was moderated by Arundhati Parmar of MedCity News, who wrote up the session in a report published November 9. Each speaker described a version of the same model: a GLP 1 prescription paired with coaching, nutrition support and digital tracking aimed at heart and metabolic health rather than weight alone. Alexander Fabry, vice president of healthcare product at Noom, summed up the idea when he told the audience, "You didn't come for a drug, you came for health." He said every GLP 1 should be used with a companion, and that the hard part is to fund that companion and build it into care delivery. Noom sells directly to consumers and gives members access to clinicians who can prescribe the drugs, plus coaches.
The other three firms sell mainly to businesses such as employers. Virta Health offers lifestyle and nutrition support to people taking GLP 1 drugs. Omada Health, which built its name on clinical evidence for its prediabetes tools, now pitches a multi condition approach, since people with weight problems often also live with diabetes, high blood pressure or joint and muscle problems. Twin Health builds a digital model of each user from smart devices and sensors, then gives tailored advice on food, sleep, activity and stress. None of this is a new approval, price or coverage decision. These GLP 1 companion programs were described as sales arguments on a conference stage, and they should be read that way until the firms publish results others can check.
| Company | Speaker on the panel | Model described | Main claim on stage |
|---|---|---|---|
| Noom | Alexander Fabry, vice president of healthcare product | Sells to consumers, offers prescribers and coaches | Every GLP 1 should come with a companion |
| Virta Health | Laura Walmsley, chief commercial officer | Sells to businesses, lifestyle and nutrition support | Over 80% compliance and engagement at one year |
| Omada Health | Wei-Li Shao, president and incoming CEO | Multi condition program for employers | Treating linked conditions together improves ROI |
| Twin Health | Adam Johnson, chief strategy officer | Sensor fed digital model of each user | Aim is to help some people stop the drug |
Adherence claims behind GLP 1 companion programs
GLP 1 adherence is the core of the pitch. Laura Walmsley, Virta Health's chief commercial officer, said GLP 1 compliance "in the wild," without support from firms like hers, sits around the 35th percentile at one year. She said that is not unlike insulin and other major medicines. With Virta, she said, more than 80% of people who start a GLP 1 are still compliant and engaged at one year. These two figures are not a like for like comparison. The MedCity report does not say how Virta measured compliance, which patients were counted, or whether the 80% figure comes from a published study. A combined measure of compliance and engagement could also count app use, not only refilled prescriptions.
The MedCity report does not say how Virta measured compliance, which patients were counted, or whether the 80% figure comes from a published study.
Why does this matter for access? Employers are pulling back mainly over price, the MedCity report says. A drug that patients stop early can add to that concern, because the plan pays for months of treatment without a lasting result. A vendor that can show people stay on treatment, or reach their goals and step down, has a story to tell plan sponsors. Twin Health's Adam Johnson went further and said the aim is to help some people get healthy enough that they no longer need the drug. "We're not here to tell you you can't have a medication," he said. The report describes no outcome data on how many Twin users have stopped, or what happened to their weight afterward.
Employer GLP 1 coverage and the ROI argument
Wei-Li Shao, president and incoming chief executive of Omada Health, framed the pitch in return on investment terms. He told the audience that healthcare cost growth in 2027 is expected to be probably the highest since 2003, a forecast he gave without a named source in the report. His argument was that buyers focused on ROI get better results when a vendor treats several linked conditions at once, because improving one condition raises the odds of improving another. That is a claim about value, not a finding the panel backed with data on stage. For workers, the practical point is that the sales talk around employer GLP 1 coverage is shifting toward GLP 1 companion programs and other services around the drug, not only the price of the pen.
Twin Health aimed its message at the same buyers. MedCity reported that the promise of weaning patients off medicine appeals to employers that have grown reluctant to cover GLP 1 drugs as costs rise. Johnson said that if a person gets healthy enough to stop, the individual wins and so does the plan sponsor. Readers following employers dropping GLP 1 coverage will see the tension here. A program built to cut drug use can help a plan budget, yet patients may fear that coverage comes with pressure to stop. The report does not say whether any employer makes drug coverage depend on joining such a program, or what happens to workers who decline.
Digital health consolidation could reshape access
Parmar asked the panel whether any of their companies would still exist two or three years from now. Johnson said the problem they work on affects a material share of the American population and that there is room for many winners, though he did not expect every point solution to last ten years. Fabry answered in a similar way, according to the report. Shao was blunter. He said GLP 1 companies are "coming out of the woodwork" and that some will be gone within 36 months. He described a spectrum, with firms that simply create access to the drugs, which he likened to "vending machines," at one end and firms that try to restrict use at the other.
Shao predicted that both ends would contract, and another panelist said she fully agreed that digital health consolidation is coming after five years of heavy market entry. For patients, a shakeout is an access question. A worker who starts a drug through an employer program, or a consumer using a direct service, may have to switch prescriber, pharmacy route or support team if a vendor is bought or closes. Before enrolling, patients can ask their plan who prescribes, who fills the drug and what happens if the vendor contract ends. Our report on the GLP 1 aftercare gap covers what can follow when support stops. This story is for information only and is not medical advice.
Conclusion
GLP 1 companion programs are now a main sales pitch to US employers weighing the cost of these drugs. The Dallas panel made strong claims on adherence and savings but showed no published data, prices or client names. Until those appear, patients and plan buyers should treat the 80% figure as a company statement, ask how any program affects their coverage, and watch for vendor exits as the market consolidates.
Source MedCity News report by Arundhati Parmar, November 9, 2026, on a panel at the INVEST Digital Health conference in Dallas on October 29, 2026
Sources
Spotted an error? Tell us through the contact form; we follow the corrections policy.